In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ZyStor Therapeutics Inc.

www.zystor.com

Latest From ZyStor Therapeutics Inc.

Licensing PARP Inhibitor A Win For BioMarin, Medivation

BioMarin’s licensing of the PARP inhibitor talazoparib to Medivation in August reduces BioMarin’s development expenses and helps it to meet its stated goal of being non-GAAP earnings positive in 2017. Medivation gets another compound it can develop in key oncology indications it is already pursuing with its core product, the prostate cancer drug Xtandi.

BioPharmaceutical Deals

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2010

Biopharma financings slumped in the third quarter of 2010 - the $1.69 billion raised in Q3 was about half of Q2's $3.37 billion. Most of the third quarter money came from VC rounds. Two-thirds of the M&A total came from J&J's $2.2 billion purchase of the 82.1% of Crucell that it didn't already own. And following a long stretch in which earlier-stage assets were grabbing the largest deal values, Q3's biopharma alliances proved the contrary - the majority of the biggest moneymakers were for Phase II and higher therapeutics.
BioPharmaceutical

Deals Shaping the Medical Industry (10/2010)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions

BioMarin acquires enzyme replacement therapy developer ZyStor

BioMarin Pharmaceutical has acquired ZyStor Therapeutics, a privately held US biotechnology company developing enzyme replacement therapies (ERTs) for the treatment of lysosomal storage disorders. ZyStor's lead product candidate, ZC-701 for the treatment of Pompe disease, is slated to enter the clinic next year.

Metabolic Disorders Deals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • ZyStor Therapeutics Inc.
  • Senior Management
  • Loren G Peterson, Pres. & CEO
    Jonathan H LeBowitz, PhD, EVP, CSO
  • Contact Info
  • ZyStor Therapeutics Inc.
    Phone: (414) 727-9777
    10437 Innovation Dr., Ste. 100
    Milwaukee, WI 53226
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register